Harvey AL. Natural products in drug discovery. 2008 …shodhganga.inflibnet.ac.in/bitstream/10603/9420/13/13_bibliography.pdfHarvey AL. Natural products in drug discovery. Drug Discovery

Bibliography

173 | P a g e Department of Pharmacognosy, JSSCP (JSS University, Mysore), Udhagamandalam-643001

BIBLIOGRAPHY

1. Harvey AL. Natural products in drug discovery. Drug Discovery Today, 2008,

13(19-20), 894-901.

2. Patwardhan B, Vaidya ADB, Chorghade M, Joshi SP. Reverse pharmacology

and systems approaches for Drug Discovery and Development, Current

Bioactive Compounds, 2008, 4(4), 1-12.

3. Patil D, Gautam M, Mishra S, Jadhav U, Suresh K, Gairola S, Jadhav SS,

Patwardhan B. Physicochemical stability and biological activity of Withania

somnifera extract on real time and accelerated storage conditions. Planta

Medica, 2010, 76, 481-488.

4. Chitalange SS, Kulkarni PS, Patil D, Patwardhan B, Nanda RK. High

performance liquid chromatographic fingerprint for quality control of

Terminalia arjuna containing Ayurvedic churna formulations. Journal of the

Association of Official Analytical Chemists, 2009, 92, 1016-20.

5. Warude D, Patwardhan, B. Botanicals: quality and regulatory issues. Journal

of Scientific and Industrial Research, 2005, 64, 83-92.

6. World Health Organization, Quality control methods for medicinal plant

materials Revised Draft Update, 1998, 1-49.

7. Saraf SA. Applications of novel drug delivery system for herbal formulations.

Fitoterapia, 2010, 81, 680-689.

8. Yaohua Hu, Peng J, Shuping W, Shikai Y, Xiang Li, Weidong Z, Runhui Liu.

Plasma pharmacochemistry based approach to screening potential bioactive

components in Huang-Lian-Jie-Du-Tang using high performance liquid

chromatography coupled with mass spectrometric detection. Journal of

Ethnopharmacology, 2012, 141, 728-735.

9. Yonghai L, Xi Zhang, Xu Liang, Xinru Liu, Weixing Dai, Shikai Yan,

Weidong Zhanga. Characterization of the constituents in rat biological fluids

after oral administration of Fufang Danshen tablets by ultra-performance

liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal

of Pharmaceutical and Biomedical Analysis, 2010, 52,155-159.

10. Khalid H, Zhari I, Amirin S, Pazillah I. Bioactive Markers Based

Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant,

Piper sarmentosum. Evidence-Based Complementary and Alternative

Medicine, 2011, 1-7.

Bibliography


11. Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R.

Pharmacokinetic study of 11-Keto beta-Boswellic acid. Phytomedicine, 2004,

11(2-3), 255-60.

12. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM,

Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and

pharmacokinetic study of oral Curcuma extract in patients with colorectal

cancer. Clinical Cancer Research, 2001, 7, 1894-900.

13. Ploeger B, Mensinga T, Sips A, Meulenbelt J, DeJongh J. A human

physiologically-based model for glycyrrhzic acid, a compound subject to

presystemic metabolism and enterohepatic cycling. Pharmaceutical Research,

2000, 17, 1516–1525.

14. The top 10 causes of death. Geneva, Switzerland: World Health Organization;

2008 (Fact sheet 310).

(http://www.who.int/mediacentre/factsheets/fs310_2008.pdf).

15. Paez KA, Zhao L, Hwang W. Rising out-of-pocket spending for chronic

conditions: a ten-year trend. Health Aff (Millwood), 2009, 28, 15-25.

16. Anonymous. Tackling the burden of chronic diseases in the USA. Lancet,

2009, 373, 185.

17. Patel V, Chatterji S, Chisholm D, Ebrahim S, Gopalakrishna G, Mathers C,

Mohan V, Prabhakaran D, Ravindran RD, Reddy KS. Chronic diseases and

injuries in India. Lancet, 2011, 377, 413-428.

18. Tiwari AK, Rao JM. Diabetes mellitus and multiple therapeutic approaches of

phytochemicals: Present status and future prospects. Current Science, 2002,

83, 30-38.

19. Abebe W. Herbal medication: potential for adverse interactions with

analgesic drugs. Journal of Clinical Pharmacy and Therapeutics, 2002, 27,

391-401.

20. Zhou S, Zhou W, Li C, Chen X, Yu X, Xue C, Herington A. Identification of

drugs that interacts with herbs in drug development. Drug Discovery Today,

2007, 12, 664-673.

21. Zhu R, Hu L, Li H, Su J, Cao Z, Zhang W. Novel Natural Inhibitors of

CYP1A2 identified by in silico and in vitro Screening. International Journal

of Molecular Science, 2011, 12, 3250-3262.

http://www.ncbi.nlm.nih.gov/pubmed/11448902

http://www.who.int/mediacentre/factsheets/fs310_2008.pdf

Bibliography


22. Guidance for industry: drug interaction studies-study design, data analysis,

and implications for dosing and labeling.2012.

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guida

nces/default.htm

23. Hu Z., Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou

S. Herb-drug interactions: a literature review. Drugs, 2005, 65, 1239-1282.

24. Iwata H, Tezukay Y, Usia T, Kadota S, Hiratsuka A, Watabe, T. Inhibition of

human liver microsomal CYP3A4 and CYP2D6 by extracts from 78 herbal

medicines Journal of Traditional Medicine, 2004, 21, 41-50.

25. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed

drugs: a systematic review. Drugs, 2001, 61, 2163-2175.

26. Indian Pharmacopoeia, Indian Pharmacopoeia commission, Ghaziabad, 2007,

2036-2037.

27. Shanmugasundaram KR, Panneezselvam C. The insulinotropic activity of

Gymnema sylvestre an Indian medical herb used in controlling Diabetes

Mellitus. Pharmacological Research Communications, 1981, 13(5), 475-486.

28. Rachh PR, Rachh MR, Ghadiya NR, Modi DC, Patel NM, Rupareliya MT.

Antihyperlipidimic activity of Gymnema sylvestre leaf extract on rats fed with

high cholesterol diet. International Journal of Pharmacology, 2010, 6(2), 138-

141.

29. Chodisetti B, Rao K, Giri A. Phytochemical analysis of Gymnema sylvestre

and evaluation of its antimicrobial activity. Natural Product Research, 2012,

DOI: 10.1080/14786419.2012.676548.

30. Kang MH, Lee MS, Choi MK, Min KS, Shibamoto T. Hypoglycemic activity

of Gymnema sylvestre extracts on oxidative stress and antioxidant status in

diabetic rats. Journal of Agricultural Food Chemistry, 2012, 60 (10), 2517-24.

31. Saneja A, Sharma C, Aneja KR, Pahwa R. Gymnema sylvestre (Gurmar): A

review. Der Pharmacia Lettre, 2010, 2(1), 275-284.

32. Srikanth AV, Sayeeda M, Lakshmi NM, Ravikumar P, Madhava RB.

Anticancer activity of Gymnema sylvestre R.Br. International Journal of

Pharmaceutical Sciences & Nanotechechnology, 2010, 3(1), 897-899.

33. Kanetkar P, Singhal R, Kamat M. Gymnema sylvestre: A memoir. Journal of

Clinical Biochemistry & Nutrition, 2007, 41(2), 77-81.

Bibliography


34. Shanmugasundaran ERB, Rajeswari G, Baskaran K, Kumar BRR,

Shanmugasundaram KR, Ahmath BK. Use of Gymnema sylvestre leaf extract

in the control of blood glucose in insulin dependent diabetes mellitus. Journal

of Ethnopharmacology, 1990, 30, 281-294.

35. Yoshikaua K, Alimotoa K, Ariharaa S, Natsuura K. Structure studies of new

antisweet constituents from Gymnema sylvestre. Tetrahedron Letters, 1989,

30, 1103-1106.

36. Trivedi PD, Pundarikakshudu K, Shah KA. Validated reverse phase liquid

chromatographic method for quantification of gymnemagenin in the Gymnema

sylvestre R. Br. leaf samples, extract and market formulation. International

Journal of Applied Sciences & Engineering, 2011, 9, 25-31.

37. Toshiaki I, Yamamoto FM, Akiko M, Hiroyuki H. High-performance liquid

chromatography-atmospheric pressure ionization mass spectrometry of

gymnemic acids, Journal of Chromatography, 1991, 557, 383-389.

38. Toshihiro Y, Kenzi M, Kenzo O, Osamu T. Quantitative analysis of

gymnemic acids by high performance liquid chromatography. Nippon

Shokuhin Kagaku Kaishi, 1994, 41, 202- 205.

39. Valivarthi SRR, Kannababu S, Gottumukkala VS. Standardisation of

Gymnema sylvestre R.Br. by high-performance thin-layer chromatography: an

improved method. Phytochemical Analysis., 2006, 17, 192-196.

40. Hamed AI, Janda B, Mahalel UA, Stochmal A, Oleszek W. Profiles of

steroidal saponins from the aerial parts of Tribulus pentandrus,

T.megistopterus subsp. pterocarpus and T. parvispinus by LC–ESI–MS/MS.

Phytochemical Analysis, 2012 DOI: 10.1002/pca.2363.




Medica, 2010, 76, 481-488.

42. Patil D, Mishra S, Gautam M, Kulkarni P, Suresh K, Gairola S, Jadhav SS,

Patwardhan B. Estimation of protoberberine alkaloids in Tinospora cordifolia

stem crude powder, processed extracts and marketed formulations using

HPLC-DAD method. Chromatographia, 2010, 71, 341-345.

Bibliography


43. Saller R, Reichling J, Phytotherapie. In: Melchart D., Brenke R., Dobos G.

Gaisbauer M., Saller R. (Eds.), Naturheilverfahren. SchattauerGmbH,

Stuttgart, 2002, 180-293.

44. . R.Bauer, Drug Inform Journal, 1998, 32, 101-110.

45. N.J.Lazarowych, P.Pekos. Drug Inform Journal, 1998, 32, 497-512.

46. Guidance for Industry on Botanical Drug Products, U.S. Department of

Health and Human Services Food and Drug Administration, Center for Drug

Evaluation& Research (CDER). 2004, 33. Available at

www.fda.gov/cder/guidance/index.htm Assessed on 10. May 2009.

47. EMEA Reflection paper on stability testing of herbal medicinal products and

traditional herbal medicinal products (EMEA/HMPC/3626/2009). 2009, 1-3.

48. World Health Organization. Quality control guidelines for medicinal plant

material. 1998, 111.

49. Zhang H, Sun Y, Duan M, Chen Y, Zhong D, Zhang H. Separation and

identification of Aconitum alkaloids and their metabolites in human urine.

Toxicology, 2005, 46, 500-506.

50. Felgines C, Talavera S, Texier O, Gil-Izquierdo A, Lamaison JL, Remesy C.

Blackberry anthocyanins are mainly recovered from urine as methylated and

glucuronidated conjugates in humans. Journal of Agricultural Food

Chemistry, 2005, 53 (20), 7721-7.

51. Naik H, Murry DJ, Kirsch LE. Fleckenstein L. Development and validation

of a high-performance liquid chromatography-mass spectroscopy assay for

determination of artesunate and dihydroartemisinin in human plasma. Journal

of Chromatography B: Analytical Technologies in the Biomedical Life

Sciences, 2005, 25, 816, 233-42.

52. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G.

Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2

with human and rodent intestine: relevance to in vivo prediction. European

Journal of Pharmaceutical Sciences, 2005, 26, 386-393.

53. Liang Y, Xie P, Chan K. Quality control of herbal medicines. Journal of

Chromatography B, 2004, 812, 53-70.

54. Xing J, Xie C, Lou H. Recent applications of liquid chromatography–mass

spectrometry in natural products bioanalysis. Journal of Pharmaceutical and

Biomedical Analysis, 2007, 44, 368-378.

http://www.fda.gov/cder/guidance/index.htm

http://www.ncbi.nlm.nih.gov/pubmed?term=Felgines%20C%5BAuthor%5D&cauthor=true&cauthor_uid=16190623

Bibliography


55. Guo J, Xu Q, Chen T. Quantitative determination of astilbin in rabbit plasma

by liquid chromatography. Journal of Chromatography B, 2004, 805, 357-

360.

56. Feras IK, Melpomeni I, Bounartzi, Ioannis N. A validated HPLC

determination of the flavone aglycone diosmetin in human plasma. Biomedical

Chromatography, 2004, 18(10), 800-804.

57. Abe E, Lemaire-HAS, Duverneuil C, Etting I, Guillot E, de Mazancourt P,

Alvarez JC. A novel LC-ESI-MS-MS method for sensitive quantification of

colchicine in human plasma: application to two case reports. Journal of

Analytical Toxicology, 2006, 30 (3), 210-5.

58. Wang S, Wang G, Li X, Sun J, Ma R, Sheng L. Simultaneous determination of

oxymatrine and its active metabolite matrine in dog plasma by liquid

chromatography-mass spectrometry and its application to pharmacokinetic

studies. Journal of Chromatography B, 2005, 817, 319-325.

59. Hao XH, Cheng G, Sun J, Zou MJ, Yu J, Zhang S, Cui FD. Validation of an

HPLC method for the determination of scutellarin in rat plasma and its

pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis,

2005, 38, 360-363,

60. Qian T, Jiang ZH, Cai Z. High-performance liquid chromatography coupled

with tandem mass spectrometry applied for metabolic study of ginsenoside

Rb1 on rat. Analytical Biochemistry, 2006, 352, 87–96.

61. Molavi A, Shayeganpour V, Somayaji S, Hamdy DR, Brocks A, Lavasanifar

GS, Samuel KJ. Development of a sensitive and specific liquid

chromatography/mass spectrometry method for the quantification of

cucurbitacin I (JSI-124) in rat plasma. Journal of Pharmacy &

Pharmaceutical Sciences, 2006, 9, 158-164.

62. Cai Z, Sinhababu AK, Harrelson S. Simultaneous quantitative cassette

analysis of drugs and detection of their metabolites by high performance liquid

chromatography/ion trap mass spectrometry. Rapid Commun Mass Spectrom,

2000, 14(18), 1637-43.

63. Cai Z, Qian T, Wong RNS, Jiang Z. Liquid chromatography-electrospray

ionization mass spectrometry for metabolism and pharmacokinetic studies of

ginsenoside Rg3. Analytica Chimica Acta, 2003, 492, 283-293.




http://www.ncbi.nlm.nih.gov/pubmed?term=Cai%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=10962484


Bibliography


64. Li HL, Zhang W, Zhang C, Liu RH Wang, XW, Wang XL, Zhu JB, Chen

CL. Bioavailabilty and pharmacokinetics of four active alkaloids of traditional

Chinese medicine Yanhuanglian in rats following intravenous and oral

administration. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41,

1342–1346.

65. Tong L, Zhou D, Gao J, Zhu Y, Sun H, Bi K. Simultaneous determination of

naringin, hesperidin, neohesperidin, naringenin and hesperetin of Fractus

aurantii extract in rat plasma by liquid chromatography tandem mass

spectrometry, Journal of Pharmaceutical and Biomedical Analysis, 2012, 58,

58-64.

66. Ma H, Wang Y, Guo T, He Z, Chang X, Pu X. Simultaneous determination of

tetrahydropalmatine, protopine, and palmatine in rat plasma by LC-ESI-MS

and its application to a pharmacokinetic study. Journal of Pharmaceutical and

Biomedical Analysis, 2009, 49, 440–446.

67. Bai X, Qu J, Lu J, Kano Y, Yuan D. Pharmacokinetics of kakkalide and its

main metabolites in rat plasma determined by HPLC-DAD and LC–MS.

Journal of Chromatography B. 2011, 879, 395–402.

68. Kamble B, Gupta A, Patil D, Janrao S, Khatal L, Duraiswamy B. Quantitative

estimation of gymnemagenin in Gymnema sylvestre extract and its marketed

formulations using the HPLC–ESI–MS/MS method. 2012, Phytochemical

analysis, DOI: 10.1002/pca.2392.

69. Ding L, Huang X, Yang J, Bian X, Zhang Z, Liu G. Determination of

glycyrrhetic acid in human plasma by LC-ESI-MS. Journal of Pharmaceutical

and Biomedical. Anal, 2006, 40, 758–762.

70. John Lin Z, Qiu SX, Wufuer A, Shum L. Simultaneous determination of

glycyrrhizin, a marker component in Radix glycyrrhizae, and its major

metabolite glycyrrhetic acid in human plasma by LC-MS/MS. Journal of

Chromatography B, 2005, 814, 201-207.

71. Gelpi E. Biomedical and biochemical applications of liquid chromatography-

mass spectrometry. Journal of Chromatography A, 1995, 703, 59-80.

72. Capek M, Jirásko R, Lísa M. Recent developments in liquid chromatography

mass-spectrometry and related techniques. Journal of Chromatography A,

2012, 1259, 3–15.

Bibliography


73. Prasad B, Garg A, Takwani H, Singh S. Metabolite identification by liquid

chromatography mass spectrometry. Trends in Analytical Chemistry, 2011, 30

(2), 360-387.

74. Calixto JB. Efficacy, safety, quality control, marketing and regulatory

guidelines for herbal medicines (phytotherapeutic agents) The medicinal use

of herbal drugs. Brazilian Journal of Medical and Biological Research, 2000,

33, 179-189.

75. De Smet PA, Brauwers JR. Pharmacokinetic evaluation of herbal remedies

basic introduction, applicability, current status and regulatory needs. Clinical

Pharmacokinetics, 1997, 32, 427–436.

76. Handa SS, Kakul MK. “Medicinal plants –priorities in Indian medicines

diverse studies and implications,” in supplement to cultivation and utilization

of medicinal plants, 1996, 33–51, Regional Research Laboratories, Jammu

Tawi,India.

77. Mills S, Bone K. Principles and Practice of Phytotherapy, Churchill

Livingstone, Edinburgh, UK, 2000.

78. Agrosi M, Mischiatti S, Harrasser PC, Savio D. Oral bioavailablity of active

principals from herbal products in humans. A study on Hypericum perforatum

extracts using the soft gelatin capsule technology. Phytomedicine, 2000, 7 (6),

455-462.

79. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of

hypericin and pseudohypericin after oral intake of the Hypericum perforatum

extract LI 160 in healthy volunteers. Journal of Geriatric Psychiatry and

Neurology, 1994, 7, 47-53.

80. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of

hyperforin from Hypericum extracts in rats and human volunteers.

Pharmacopsyciatry, 1998, 31, 36-43.

81. Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme

inhibition properties of Pomgranate seed oil and fermented juice flavonoids.

Journal of Ethnopharmacology, 1999, 66 (1), 11-17.

82. Doyle B, Griffiths LA. The metabolism of ellagic acid in the rat. Xenobiotica,

1980, 10, 247.

Bibliography


83. Lei F, Xing DM, LanXiang ,Yu-NanZhao,WeiWang ,Lu-JunZhang, Li-JunDu,

Pharmacokinetic study of ellagic acid in rat after oral administration of

pomegranate leaf extract. Journal of Chromatography B, 2003, 796, 189–194.

84. Sharma S, Hawaii V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R.

Pharmacokinetic study of 11- Keto β-Boswellic Acid. Phytomedeicine, 2004,

11, 255-260.

85. Panossian A, Hovhannisyan A, Mamikonyan G, Abrahamian H,

Hambardzumyan E, Cabrielianl E, Goukasova G, Wikman G, Wagner H.

Pharmacokinetic and oral bioavailability of andrographolide from

Andrographis paniculata fixed combination Kan Jang in rats and human.

Phytomedicine, 2000, 7 (5), 351-364.

86. Baoqi W, Zhigong P, Congying W. Study on pharmacokinetic parameters of

andrographolide in rabbit plasma by chemiluminescence. Shenyang Yaoke

Daxue Xuebao, 1995, 12 (l), 5- 9.

87. Jayeul L, Euiju L, Donghyun K, Junhee L, Junghee Y, Byunghee K,

Studies on absorption, distribution and metabolism of ginseng in humans after

oral administration. Journal of Ethnopharmacology, 2009, 122, 143–148.

88. Fujisawa K, Tandon BN. Therapeutic approach to the chronic active

liver disease: Summary of a satellite symposium. In: Nishioka K, Suzuki

H, Mishiro S, Oda T,eds. Viral Hepatitis and Liver Disease. Tokyo:

Springer-Verlag, 1994, 662-665.

89. Akao T, Akao T, Hattori M, Kanaoka M K, Yamamoto T, Kobashi NK.

Hydrolysis of glycyrrhizin to 18 beta-glycyrrhetyl monoglucuronide by

lysosomal beta-D glucuronidase of animal livers. Biochemical Pharmacology,

1991, 41, 1025-1029.

90. Hattori M, Sakamoto T, Yamagishi T, Sakamoto K, Konishi K, Kobashi K.

N. Metabolism of glycyrrhizin by human intestinal flora.II. Isolation and

characterization of human intestinal bacteria capable of metabolizing

glycyrrhizin and related compounds. Chemical & Pharmaceutical Bulletin

1985, 33, 210-217.

91. Vibha JB, Choudhary K, Singh M, Rathore MS, Shekhawat NS, A Study on

pharmacokinetics and therapeutic efficacy of Glycyrrhiza glabra: A miracle

medicinal herb. Botany Research International, 2009, 2 (3), 157-163.

Bibliography


92. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin:

preclinical and clinical studies. Anticancer Research, 2003, 23, 363-98.

93. Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW.

Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer

Letters, 1997, 116, 197–203.

94. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon

carcinogenesis by dietary curcumin, a naturally occurring plant phenolic

compound. Cancer Research, 1995, 55, 259-66.

95. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H. Antihepatotoxic

principles of Curcuma longa rhizomes. Planta Medica, 1983, 49, 185-7.

96. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of

curcumin (1, 7-bis- (4- hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione)

in the rat. Xenobiotica, 1978, 8,761-8.

97. Wahlstrom B, Blennow G.A. study on the fate of curcumin in the rat. Acta

Pharmacologica et Toxicologica (Copenh), 1978, 43, 86-92.

98. Goel A, Kunnumakkara AB, Agarwal BB. Curcumin as ‘Curecumin’ From

kitchen to clinic. Biochemical Pharmacology, 2008, 75, 787–809.

99. Hussain K, Ismail Z, Sadikun A, Ibrahim P. Bioactive markers based

pharmacokinetic evaluation of extracts of a traditional medicinal plant, Piper

sarmentosum. Evidence-Based Complementary and Alternative Medicine,

2011, 1-7. doi:10.1093/ecam/nep143.

100. Kyung-Mi J, Lee JH, Jeon HY, Park CW, Honga DK, Jeong HJ, Lee SJ, Lee

SY, Lim KM. Pharmacokinetic study of ginsenoside Re with pure ginsenoside

Re and ginseng berry extracts in mouse using ultra performance liquid

chromatography /mass spectrometric method. Journal of Pharmaceutical and

Biomedical Analysis, 2010, 51, 278–283.

101. Chen LC, Lee MH, Chou MH, Lin, MF, Yang LL. Pharmacokinetic study of

paeoniflorin in mice after oral administration of Paeoniae radix extract.

Journal of Chromatography B, 1999, 735, 33–40.

102. Suryawanshi SR, Asthana K, Gupta RC. Simultaneous estimation of

mangiferin and four secoiridoid glycosides in rat plasma using liquid

chromatography tandem masss pectrometry and its application to

pharmacokinetic study of herbal preparation. Journal of Chromatography B,

2007, 858, 211–219.

Bibliography


103. Lee JH, Kim JM, Kim C. Pharmacokinetic analysis of rhein in Rheum

undulatum L. Journal of Ethnopharmacology, 2003, 84, 5-9.

104. Hua X, Fu YJ, Zu YG, Zhang L, Wang W, Luo M. Determination of

pinostrobin in rat plasma by LC–MS/MS: Application to pharmacokinetics.

Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 841–845.

105. Tanga L, Gonga Y, Lva C, Yea L, Liua L, Liua Z. Pharmacokinetics

of aconitine as the targeted marker of Fuzi (Aconitum carmichaeli) following

single and multiple oral administrations of Fuzi extracts in rat by

UPLC/MS/MS. Ethnopharmacology, 2011, doi:10.1016/j.jep.2011.08.070.

106. Juan P, Zengfeng S, Chen MA. Emodin studies on pharmacokinetics and

distribution in rat liver after Polygonum cuspidatum sieb. et Zucc. extract

administration. world science and technology. Modernisation of traditional

chinese medicine and Materia Medica, 2008, 10(1), 64-67.

107. Xie J, Ding C, Ge Q, Zhou Z, Zhi X. Simultaneous determination of

ginkgolides A, B, C and bilobalide in plasma by LC–MS/MS and its

application to the pharmacokinetic Study of Ginkgo biloba extract in rats.

Journal of Chromatography B, 2008, 864, 87–94.

108. Peng SW, Shen P, Lee L, Li J, Yong EL. Pharmacokinetics of

prenylflavonoids and correlations with the dynamics of estrogen action in sera

following ingestion of a standardized epimedium extract. Journal of

Pharmaceutical and Biomedical Analysis, 2009, 50, 216–223.

109. Saraf AS. Applications of novel drug delivery system for herbal

formulations. Fitoterapia, 2010, 81(7), 680-689.

110. Iosio T, Voinovich D, Perissutti B, Serdoz F, Hasa D, Grabnar I, Zara G.P,

Muntoni E, Pinto J.F,. Acqua S D. Oral bioavailability of silymarin

phytocomplex formulated as self-emulsifying pellets. Phytomedicine,

2011,18(6), 433-538.

111. Chen Y, Lin X, Park H, Greever R. Study of artemisinin nanocapsules as

anticancer drug delivery systems. Nanomedicine: Nanotechnology, Biology,

and Medicine, 2009, 5, 316–322.

112. Khandavilli S, Panchagnula R. Nanoemulsions as Versatile Formulations for

Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats. Journal of

Investigative Dermatology, 2007, 127, 154–162.



Bibliography


113. Mohanty CS, Sahoo K. The in vitro stability and in vivo pharmacokinetics of

curcumin prepared as an aqueous nanoparticulate formulation, Biomaterials,

2010, 31, 6597-6611.

114. Swapna M, Sibabarata M, Mukul kumar B. Evaluation of the in vivo activity

and toxicity of Amarogentin, an anti-leishmanial agent in both liposomes and

niosome forms. Journal of antimicrobial chemotherapy, 1999, 44, 791-794.

115. Kidd PM. Bioavailability and activity of phytosome complexes from

botanical polyphenols: The Silymarin, Curcumin, Green Tea, and Grape Seed

Extracts. Alternative Medicine Review, 2009, 14(3), 226-246.

116. Milane HA, Ubeaud G, Thierry F, Jung VL. Isolation of quercetin’s salts

and studies of their physicochemical properties and antioxidant relationships.

Bioorganic & Medicinal Chemistry, 2004, 12, 3627-3635.

117. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin

encapsulated PLGA nanoparticles for improved therapeutic effects in

metastatic cancer cells. Journal of Colloid and Interface Science, 2010, 351,

19–29.

118. Yongmei H, Fenglin Z, Na L, Yanhong Y, Kean L. Studies on a high

encapsulation of colchicine by a niosome system. International Journal of

Pharmaceutics, 2002, 244, 73-80.

119. Sanoj R, Muthunarayanan M, Muthuchelian K, Chennazhi KP , Shanti N,

Jayakumar R. Saponin-loaded chitosan nanoparticles and their cytotoxicity to

cancer cell lines in vitro. Carbohydrate Polymers, 2011, 84, 407-416.

120. Laura S, Antonella S, Mariateresa C, Francesco C, D'Arrigo M, Domenico

T, Rao F, R Giuseppe. Phytocomplexes from liquorice (Glycyrrhiza glabra

L.) leaves Chemical characterization and evaluation of their antioxidant, anti-

genotoxic and anti-inflammatory activity. Fitoterapia, 2011, 82, 546-556.

121. You J, Cui FD, Han X, Wang YS, Yang L, Yu YW, Li QP. Study of the

preparation of sustained-release microspheres containing zedoary turmeric oil

by the emulsion-solvent-diffusion method and evaluation of the self-

emulsification and bioavailability of the oil. Colloids Surface B Biointerfaces,

2006, 48(1), 35-41.

122. Zheng Y, Hou SX, Chen T, Lu Y. Preparation and characterization of

transfersomes of three drugs in vitro. China Journal of Chinese Materia

Medica, 2006, 31(9), 728-31.

Bibliography


123. Zhaowu Z, Xiaoli W, Yangde Z, Nianfeng L. Preparation of matrine

ethosome, its percutaneous permeation in vitro and anti-inflammatory activity

in vivo in rats. Journal of Liposome Research, 2009, 19(2),155-62.

124. Cristiano C. Herbal interactions on absorption of drugs: Mechanisms of

action and clinical risk assessment. Pharmacological Research, 2010, 62, 207-

227.

125. (a) Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS.

Factors associated with dietary supplement use among prescription medication

users. Archives of Internal Medicine, 2006, 166, 1968-74.

(b) Abebe W. Herbal medication: potential for adverse interactions with

analgesic drugs. Journal of Clinical and Pharmaceutical Therapeutics, 2002,

27, 391–401.

126. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA,

Schoenberger NE. Ginkgo biloba extract: mechanisms and clinical indications.

Archives of Physical Medicine and Rehabilitation, 2000, 81, 668-67.

127. Zhang XY, Zhou DF, Su JM, Zhang PY. The effect of extract of Ginkgo

biloba added to haloperidol on superoxide dismutase in inpatients with chronic

schizophrenia. Journal of Clinical Psychopharmacology, 2001, 21, 85-88.

128. Zhang XY, Zhou D.F., Su J.M., Zhang P.Y. The effect of extract of Ginkgo

biloba added to haloperidol on superoxide dismutase in inpatients with chronic

schizophrenia. Journal of Clinical Psychopharmacology, 2001, 21, 85-88.

129. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed

drugs: a systematic review. Drugs, 2001, 61, 2163-2175.

130. Aslam M, Stockley IH. Interaction between curry ingredient (karela) and

drug (chlorpropamide). Lancet, 1979, 1, 607.

131. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum

perforatum). Lancet, 2000, 355, 576-577.

132. Ernst E. Second thoughts about safety of St John's wort. Lancet, 1999, 354,

2014-2016.

133. Singh YN. Kava: an overview. Journal of Ethnopharmacology, 1992, 37,

13-45.

134. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine

antagonism. Journal of Neurology Neurosurgery & Psychiatry, 1995, 58, 639-

640.

Bibliography


135. Kuhn MA. 2002. Herbal remedies: drug-herb interactions. Critical Care

Nurse, 2002, 22, 22-28.

136. Kuhn M, Winston D. Herbal Therapy and Supplements: A Scientific and

Traditional Approach. Philadelphia, Pa: 2001, JB Lippincott.

137. Smith M. Drug interactions with natural health products/dietary

supplements: a survival guide. Paper presented at: Complementary and

Alternative Medicine: Implications for Clinical Practice and State-of-the-

Science Symposia; Boston, 2000, Mass.

138. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I.

Pharmacokinetic interaction of digoxin with an herbal extract from St John's

wort (Hypericum perforatum). Clinical Pharmacology & Therapeutics, 1999,

66, 338-345.

139. Sikka R, Magauran B, Ulrich A, Shannon M. 2005. Bench to bedside:

Pharmacogenomics, adverse drug interactions, and the cytochrome P450

system. Academic Emergency Medicine, 2005, 12, 1227-1235.

140. Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug

interactions: mechanisms involved and their medical implications. Journal of

Alternative and Complementary Medicine, 2002, 8, 293-308.

141. Estabrook RW. The remarkable P450s: a historical overview of these

versatile hemeprotein catalysts. The Journal of the Federation of American

Societies for Experimental Biology, 1996, 10, 202-204.

142. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL,

Zhou S. Herb-drug interactions: a literature review. Drugs, 2005, 65, 1239-

1282.

143. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE.

Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A

metabolism in a patient after liver transplantation. Journal Hepatology, 2000,

33, 853-855.

144. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug

interaction between St. John's wort and cyclosporine. Annals of

Pharmacotherapy. 2000, 34, 1013-1016.

145. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart

transplant rejection due to St John's wort. Lancet, 2000, 355, 548-549.

Bibliography


146. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction

between St. John's wort and theophylline. Annals of Pharmacotherapy, 1999,

33, 502.

147. Hiwale AR, Dhuley JN, Naik SR. Effect of co-administration of piperine

on pharmacokinetics of beta-lactam antibiotics in rats. Indian Journal of

Experimental Biology, 2002, 40, 277- 281.

148. Gupta SK, Bansal P, Bhardwaj RK, Velpandian T. Comparative anti-

nociceptive, anti-inflammatory and toxicity profile of nimesulide vs

nimesulide and piperine combination. Pharmacology Research, 2000, 41, 657-

662.

149. Mujumdar AM, Dhuley JN, Deshmukh VK, Raman PH, Thorat SL, Naik

SR. Effect of piperine on pentobarbitone induced hypnosis in rats. Indian

Journal of Experimental Biology, 1990, 28, 486-487.

150. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence

of piperine on the pharmacokinetics of curcumin in animals and human

volunteers. Planta Medica, 1998, 64, 353-356.

151. BanoG, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of

piperine on bioavailability and pharmacokinetics of propranolol and

theophylline in healthy volunteers. European Journal of Clinical

Pharmacology, 1991, 41, 615-617.

152. Ching MS, Bichara N, Blake CL, Ghabrial H, Tukey RH, Smallwood RA.

Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human

cytochrome P4501A1 and P4501A2. Drug Metabolism & Disposition, 1996,

24, 692-694.

153. Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of

piperine on bioavailability and pharmacokinetics of propranolol and

theophylline in healthy volunteers. European Journal of Clinical

Pharmacology, 1991, 41, 615-617.

154. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver

microsomes: inhibition studies. Journal of Pharmacology and Experimental

Therapeutics, 1996, 276, 912-917.

155. Lin SP, Tsai SY, Hou YC, Chao PD. Glycyrrhizin and licorice significantly

affect the pharmacokinetics of methotrexate in rats. Journal of Agricultural

and Food Chemistry, 2009, 57, 1854-1859.

Bibliography


156. Chiang HM, Fang SH, Wen KC, Hsiu SL, Tsai SY, Hou YC, Chi YC, Chao

PD. Life-threatening interaction between the root extract of Pueraria lobata

and methotrexate in rats. Toxicology and Applied Pharmacology, 2005, 209,

263-268.

157. Angelo A. Herb–drug interactions: an overview of the clinical evidence.

Fundamental & Clinical Pharmacology, 2004, 19, 1–16

158. Ernst E. Possible interactions between synthetic and herbal medicinal

products. Part 1: a systematic review of the indirect evidence. Perfusion, 2000,

13, 2200–2211.

159. Keshavamurthy KR, Yoganarasimhan SN, "Flora of Coorg - Karnataka";

Vimsat publishers, Bangalore, 1990, 282.

160. Agnihotri AK, Khatoon S, Agarwal M, Rawat AS, Mehrota S, Pushpgandan

P. Pharmacognostical evaluation of Gymnema sylvestre R. Br. Natural

Products Science, 2004, 10(4), 168–172.

161. Madhurima SH, Ansari P, Alam S, Ahmad MS, Akhtar S. Pharmacognostic

and phytochemical analysis of Gymnema sylvestre R.Br. Leaves. Journal of

Herbal Medicine & Toxicology, 2009, 3 (1), 73-80.

162. Indian Medicinal Plants, A Compendium of 500 species, Orient Longman

Ltd., Madras. 1995, 3, 107-109.

163. Nadkarni KM. Indian Materia Medica , Popular prakashan, Bombay. 1993,

1,596-599.

164. Bhava prakash nigunta, Motilal banarsidas publications, 1998, 256.

165. Srikanth AV, Sayeeda M, Lakshmi NM, Ravi Kumar P , Madhava RB.

Anticancer Activity of Gymnema sylvestre R.Br. International Journal of

Pharmaceutical Sciences and Nanotechnology, 2010, 3(1), 897-899.

166. Khanna VG, Krishnan K, Glulia G. Leishmanicidal activity of saponins

isolated from the leaves of Eclipta prostrata and Gymnema sylvestre. Indian

Journal of Pharmacology, 2009, 41(1), 32-35.

167. Satdive RK, Abhilash P, Fulzele DP. Antimicrobial activity of Gymnema

sylvestre leaf extract. Fitoterapia, 2003, 74, 699-701.

168. Saneja A, Sharma C, Aneja KR, Pahwa R. Gymnema sylvestre (Gurmar): A

Review. Der Pharmacia Lettre, 2010, 2(1), 275-284.

Bibliography


169. Malik JK, Manvi FV, Alagawadi KR, Noolvi M. Evaluation of anti-

inflammatory activity of Gymnema sylvestre leaves extracts in rats.

International Journal of Green Pharmacy, 2008, 2(2), 114-15.

170. Warren RP, Warren RM, Weninger MG. "Inhibition of the sweet taste by

Gymnema sylvestre", Nature, 1969, 223, 94-95.

171. Gupta SS, Seth CB. “Experimental studies on pituitary diabetics Part II.

Comparison of blood sugar level in normal and anterior pituitary extract

induced hyperglycaemic rats treated with a few Ayurvedic remedies”, Indian

Journal of Medical Research, 1962, 50(5), 708 - 714.

172. Fushiki T, Kojima A, Imoto T, Inoue K, Sugimoto E, "Extract of Gymnema

sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated

gastric inhibitory peptide secretion in rats", Journal of Nutrition, 1992, 122,

2367-2373.

173. Shanmugasundaram ERB, Gopinath KL, Shanmugasundaram KR,

Rajendran VM. “Possible regeneration of the islets of langerhans in

streptozotocin- diabetic rats given Gymnema sylvestre leaf extracts” Journal of


174. Kuzuko Y, Kayoko A, Shigenoby A, Kouji M. “Structure studies of new

anitsweet constituents from Gymnema sylvestre”. Tetrahedron letters, 1989,

30(9),1130-1106.

175. Hong-Min I, Fumiyuki K, Yoshisuke T, “Isolation and Structure elucidation

of Gymnemic Acids, antisweet principles Gymnema sylvestre”, Chemical &

Pharmaceutical Bulletin, 1992, 40(6), 1366-1375.

176. Masayuki Y, Toshiyuki M, Masashi K, Yuhao L, Nubotoshi M, Johji Y,

Hisash M. “Medicinal Food stuffs (IX1) the inhibitors of glucose absorption

from the leaves of Gymnema sylvestre R.Br. (Asclepiadaceae): Structures of

Gymneomosides A and B” Chemical & Pharmaceutical Bulletin, 1997,

45(10),1671-1676.

177. Sahu NP, Mahato SB, Sarkar SK, Poddar G. Triterpenoid saponins from

Gymnema sylvestre. phytochemistry, 1996, 41(4), 1181-1185.

178. Davis SN. The role of glimepiride in the effective management of Type 2

diabetes. Journal of Diabetes and Its Complications, 2004, 18, 367–376.

179. Holstein A, Plaschke A, Egberts EH. Lower incidence of Severe

hypoglycaemia in patients with Type 2 diabetes treated with glimepiride

Bibliography


versus glibenclamide. Diabetes and Metabolism Research and Reviews, 2001,

17, 467–473.

180. Gregorio F, Ambrosi F, Cristallini S, Filipponi P, Santeusanio F. Effects of

glimepiride on insulin and glucagon release from isolated rat pancreas at

different glucose concentrations. Acta Diabetologica, 1996, 33, 25–29.

181. Riddle M, McDaniel P, Bugos C. First-dose C-peptide response and risk of

hypoglycemia are lower with glimepiride than glyburide(abstract). Diabetes

Care, 2001, 50(l2), A129.

182. PAR Glimepiride 1mg, 2mg , 3mg, 4mg & 6mg tablets PL 27583/0119-

0123, UK/H/1508/001-005/DC. Medicines and healthcare products regulatory

agency.

183. Eberhard D. Clinical profile of glimepiride. Diabetes Research and Clinical

Practice, 1995, 28, 139-146.

184. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M.

Effect of CYP2C9 genetic polymorphisms on the efficacy and

pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes

Research and Clinical Practice, 2006, 72, 148–154.

185. Maged MY, Saleh NMWAFY, Protective potential of Glimepiride and

Nerium oleander extract on lipid profile, body growth rate, and renal function

in streptozotocin-induced diabetic rats. Turkish Journal of Biology, 2007, 31,

95-102.

186. Annonymus. Standards of medical care in diabetes. Diabetes Care, 2009,

32(1), 13-61.

187. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use

of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia,

2010, 53, 809-820.

188. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome:

systematic review and meta-analysis. British Medical Journal, 2003, 327, 951-

953.

189. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N.

Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, 893-894.

190. Ibanez L, Ong K, Valls C, Marcos MV, Dunger DB, Zegher F. Metformin

treatment to prevent early puberty in girls with precocious pubarche. Journal

of Clinical Endocrinology & Metabolism, 2006, 91, 2888-2891.

Bibliography


191. Scheen, A.J. Clinical pharmacokinetics of metformin. Clinical

Pharmacokinetics, 1996, 30, 359-371.

192. Bristol-Myers Squibb. U.S. Food and Drug Administration. 2008.

Glucophage® (metformin hydrochloride tablets) Label Information.

193. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G., Bondioli

A, Conti F. Disposition of metformin (N,N-dimethylbiguanide) in man.

Clinical Pharmacology & Therapeutics, 1978, 24, 683-693.

194. Choi YH, Lee MG. Effects of enzyme inducers and inhibitors on the

pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and

3A1/2 for the metabolism of metformin. British Journal of Pharmacology,

2006, 149, 424-430.

195. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral

organic cation transporter hOCT2. Pharmacological Research, 2005, 22, 255-

259.

196. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of

metformin renal tubular secretion by cimetidine in man. British Journal of

Clinical Pharmacology, 1987, 23, 545-551.

197. Kudolo GB, Wang W, Javors M, Blodgett J. The effect of the ingestion of

Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in

non-diabetic and type 2 diabetic subjects-a double blind placebo-controlled,

crossover study. Clinical Nutrition, 2006, 25, 606-616.

198. Choi YH, Lee I, Lee MG. Effects of bacterial lipopolysaccharide on the

pharmacokinetics of metformin in rats. International Journal of Pharmacy,

2007, 337, 194-201.

199. Cho YK, Choi YH, Kim SH, Lee MG. Effects of Escherichia coli

lipopolysaccharide on the metformin pharmacokinetics in rats. Xenobiotica,

2009, 39, 946-954.

200. Michael UA, Uzuegbu BD, Okoye C ,Theophine F, Uzor P, Maxwell AO,

Benson VA. Antidiabetic effect of combined aqueous leaf extract of Vernonia

amygdalina and Metformin in rats. Journal of Basic and Clinical Pharmacy,

2010, 1(3), 197-202.

201. Kudolo GB, Wang W, Javors M, Blodgett J. The effect of the ingestion of

Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in

Bibliography


non-diabetic and type 2 diabetic subjects-a double blind placebo-controlled,

crossover study. Clinical Nutrition, 2006, 25, 606-616.

202. Choi YH, Lee I, Lee MG. Effects of bacterial lipopolysaccharide on the

pharmacokinetics of metformin in rats. International Journal of Pharmacy,

2007, 337, 194-201.

203. Cho YK, Choi YH, Kim SH, Lee MG. Effects of Escherichia coli

lipopolysaccharide on the metformin pharmacokinetics in rats. Xenobiotica,

2009, 39, 946-954.

204. Michael UA, Uzuegbu BD, Okoye C ,Theophine F, Uzor P, Maxwell AO,

Benson VA. Antidiabetic effect of combined aqueous leaf extract of Vernonia

amygdalina and Metformin in rats. Journal of Basic and Clinical Pharmacy,

2010, 1(3), 197-202.

205. Park JW, Choi KH. Acid- Base Equilibria and related properties of chitosan

Bulletin of Korean Chemical society, 1983, 4(2) 68-71.

206. Nair R, Reddy H, Ashok Kumar CK, Jayraj KK. Application of chitosan

microspheres as drug carriers : a review. Journal of Pharmaceutical Sciences

& Research, 2009, 1(2), 1-12.

207. Dasha M, Chiellini F , Ottenbriteb RM, Chiellini E. Chitosan—A versatile

semi-synthetic polymer in biomedical applications. Progress in Polymer

Science, 2011, 36, 981-1014.

208. Harish KV, Tharanathan RN. Chitin/chitosan:modifications and their

unlimited application Potential-an overview. Trends in Food Science &

Technology, 2007,18, 117-131.

209. Astete CE, Sabliov CM. Synthesis and characterization of PLGA

nanoparticles. Journal of Biomaterials Science - Polymer Edition, 2006, 17(3),

247–289.

210. Makadia HK, Siege SJ. Poly Lactic-co Glycolic Acid (PLGA) as

Biodegradable Controlled Drug Delivery Carrier. Polymers, 2011, 3, 1377-

1397.

211. Yang YY, Chung TS. Morphology, drug distribution, and in vitro release

profiles of Biodegradable polymeric microspheres containing protein

fabricated by double-emulsion solvent extraction/evaporation method.

Biomaterials, 2001, 22, 231–241.

Bibliography


212. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS,

Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of

PLGA and PLGA-mPEG nanoparticles. International Journal of Pharmacy,

2001, 221,143–152.

213. Bazile DV, Ropert C, Huve P, Verrecchia T, Marlard M, Frydman A,

Veillard M, Spenlehauer G. Body distribution of fully biodegradable [14C]

poly(lacticacid) nanoparticles coated with albumin after parenteral

administration to rats. Biomaterials, 1992, 13, 1093–1102.

214. ‘Gymnema sylvestre’ Master document, 1-20, developed by Quality Control

Dept Natural remedies Pvt Ltd. Bangalore, India.

215. ICH Q2B, Validation of analytical procedure: Methodology International

conference on hormonisation, Geneva, 1996, 1-11.

216. Sangster J. Octanol-water partition coefficients. Fundamentals of physical

chemistry, 1997, vol 2 Wiley series in solution chemistry. Chichester: John

Wiley & Sons Ltd.

217. OECD, Guideline for testing of chemicals, 423, 2001, 1-14.

218. Guidance for Industry: Bioanalytical Method Validation, USFDA. 2001, 1-

22. http://www.fda.gov/cder/guidance/index.htm.

219. Rejinold NS, Muthunarayanan M, Muthuchelian K, Chennazhi KP, Nair SV,

Jayakumar R. Saponin-loaded chitosan nanoparticles and their cytotoxicity to

cancer cell lines in vitro. Carbohydrate Polymers, 2011, 84, 407-416.

220. Gupta H, Mohammed A, Khar RK, Asgar A, Aseemn B, Mittal G.

Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.

Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 324-333.

221. Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate-

chitosan nanoparticles loaded with 5-FU for ocular delivery: In vitro

characterization and in vivo study in rabbit eye. European Journal of

Pharmaceutical Sciences, 2012, 47(4), 678-685.

222. Hadi AM, Genevi E, Thierry FV, Louis J. Isolation of quercetin’s salts and

studies of their physicochemical properties and antioxidant relationships.

Bioorganic & Medicinal Chemistry, 2004, 12, 3627-3635.

223. Strelow EWE, Toerien FVS, Weinert CHSW. Accurate determination of

traces of sodium and potassium in rocks by ion exchange followed by atomic

absorption spectroscopy. Analytica Chimica Acta, 1970, 50(3), 399-405.

http://www.fda.gov/cder/guidance/index.htm

Bibliography


224. Pitchai D, James E, Khanzan AMMF. A novel dihydroxy gymnemic

triacetate isolated from Gymnema sylvestre possessing normoglycemic and

hypolipidemic activity on STZ-induced diabetic rats. Journal of


225. Sanjay P, Nirav G, Ashok S, Anand S. In vitro cytotoxicity activity of

Solanum nigrum extract against Hela cell line and vero cell line. International

Journal of Pharmacy and Pharmaceutical Sciences, 2009, 1,(1), 38-46.

226. Elena C, Marisela T, Jianni X, Sucha S, Dale EJ. Interactions between

traditional Chinese medicines and Western therapeutics. Current Opinion in

Drug Discovery & Development, 2010, 13(1), 50-65.

227. Laura G, Esther S, Maria JO, Cristina V, Cinta B, Mique M, Mayte B, Anna

A, Santiago GV, Gerard P. Identification of Novel human dipeptidyl

peptidase-IV inhibitors of natural origin (PartII): in silico prediction

antidiabetic extracts. PLoSONE, 2012, 7(9), 1-7.

228. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. C-peptide, Na+,

K+-ATPase, and Diabetes. Experimental Diabetes.Research, 2004, 5, 37–50.

229. Catherine K, Fabrice B, Kiriaki P, Vassilis D, Philippe C. Evaluation of

aldose reductase inhibition and docking studies of 6’-nitro and 6’,6”-

dinitrorosmarinic acids. European Journal of Medicinal Chemistry, 2010, 45,

1663–1666.

230. Lala LG, D’Mello PM, Naik SR. Pharmacokinetic and pharmacodynamic

studies on interaction of “Trikatu” with diclofenac sodium. Journal of

Ethnopharmacology, 2004, 91, 277–280.

231. Fakeye TO, Oladipupo T, Showande O, Ogunremi Y. Effects of Co-

administration of extract of Carica papaya Linn (family Cariaceae) on activity

of two oral hypoglycemic agents. Tropical Journal of Pharmaceutical

Research, 2007, 6(1), 671-678.

232. Kyung-Mi J, Ji-Hae L, Hee-Young J, Chan-Woong P, Deok-Ki H, Hye-Jin

J, Sang JL, Seok-Yong L, Kyung-Min L. Pharmacokinetic study of

ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse

using ultra performance liquid chromatography/mass spectrometric method.

Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 278–283.

233. Warude D, Patwardhan B. Botanicals: quality and regulatory issues. Journal

of Scientific and Industrial Research, 2005, 64: 83-92.

Bibliography


234. World Health Organization, Quality control methods for medicinal plant

materials - Revised Draft Update, 1998, 1-49.




Medica, 2010, 76, 481-488.

236. Chitalange SS, Kulkarni PS, Patil DL, Patwardhan B, Nanda RK. High

performance liquid chromatographic fingerprint for quality control of

Terminalia arjuna containing Ayurvedic churna formulations. Journal of the

Association of Official Analytical Chemists, 2009, 92, 1016-20.

237. Patel K, Gadewar M, Tripathi R, Patel DK.. Pharmacological and analytical

aspects of gymnemic acid: a concise report. Asian Pacific Journal of Tropical

Disease, 2012, 414-416.

238. Yoshikaua K, Alimotoa K, Ariharaa S, Natsuura K. Structure studies of new

antisweet constituents from Gymnema sylvestre. Tetrahedron Letters, 1989,

30, 1103-1106.




Journal of Applied Sciences and Engineering, 2011, 9, 25-31.

240. Toshiaki I, Yamamoto FM, Akiko M, Hiroyuki H. High-performance liquid

chromatography-atmospheric pressure ionization mass spectrometry of

gymnemic acids. Journal of Chromatography, 1991, 557, 383-389.

241. Toshihiro Y, Kenzi M, Kenzo O, Osamu T. Quantitative analysis of

gymnemic acids by high performance liquid chromatography. Nippon

Shokuhin Kagaku Kaishi, 1994, 41, 202- 205.



improved method. Phytochemical Analysis, 2006, 17, 192-196.

243. Hamed A, I, Janda B, Mahalel UA, Stochmal A, Oleszek W. Profiles of

steroidal saponins from the aerial parts of Tribulus pentandrus, T.

megistopterus sub sp. pterocarpus and T. parvispinus by LC–ESI–MS/MS.

Q11. Phytochemical Analasis, 2012, DOI: 10.1002/pca.2363.

Bibliography


244. Patil D, Gautam M, Mishra S, Jadhav U, Suresh K, Gairola S, Jadhav S.S,



Medica, 2010, 76, 481-488.

245. Patil D, Mishra S, Gautam M, Kulkarni P, Suresh K, Gairola S, Jadhav SS,

Patwardhan B. Estimation of protoberberine alkaloids in Tinospora cordifolia

stem crude powder, processed extracts and marketed formulations using

HPLC-DAD method. Chromatographia, 2010, 71, 341-345.



improved method. Phytochemical Analasis, 2006, 17, 192-196.

247. Yumiko N, Yukari T, Yasuhide T, Tadashi S. Fecal steroid excretion is

increased in rats by oral administration of gymnemic acids contained in

Gymnema sylvestre leaves. Journal of Nutrition, 1999, 129, 1214–1222.

248. Chattopadhyay RR. Possible mechanism of antihyperglycemic effect of

Gymnema sylvestre leaf extract, Part I. General Pharmacology, 1998, 31(3),

495-496.

249. Reinhold H, Nordman CE. The Crystal Structure of the Triterpene

Gymnemagenin, C30H5oO6. Acta Crystalographica, 1974, B30, 1435.

250. SubbaRao G, Sinsheimer JE. Constituents from Gymnema sylvestre Leaves

VIII: Isolation, Chemistry, and Derivatives of Gymnemagenin and

Gymnestrogenin. Journal of Pharmaceutical Sciences, 1971, 60(2), 190-192.

251. Persaud SJ, Al-Majed H, Raman A and Jones PM. Gymnema sylvestre

stimulates insulin release in vitro by increased membrane permeability.

Journal of Endocrinology, 1999, 163, 207-212.

252. Trivedi PD, Pundarikakshudu K. Isolation of gymnemagenin and

development and comparision of the validated HPLC and HPTLC methods for

estimation of gymnemagenin from plant leaves, market extract and

formulation. American Association of Pharmaceutical Sciences Abstract,

2009.

253. Elusiyan CA, Msagati TAM, Shode FO, Mamba BB. Measurements of

distribution coefficients and lipophilicity values for oleanolic acid and

betulinic acid extracted from indigenous plants by hollow fibre supported

Bibliography


liquid membrane. Bulletin of Chemical Society Ethiopia, 2011, 25(3), 321-

332.

254. Guidance for Industry: Bioanalytical Method Validation, United States Food

Drug & Administration (USFDA), 2001.

255. Lavie D, Glotter E, Shvo Y. Constituents of Withania somnifera Dun. Part

IV. The structure of withaferin A. Journal of American Chemical Society,

1965, 30, 7517-7531.

256. Gopinath R, Naidu RAS. Pharmaceutical Preformulation Studies – Current

Review International Journal of Pharmaceutical & Biological Archives, 2011,

2(5), 1391-1400.

257. Pakkir Mohamed SA, Janakiraman K. A review of on preformulation studies

of drugs. International Journal of Pharmaceutical Research and Development,

2012, 4(5), 64-74.

258. Indian Pharmacopoeia, Indian Pharmacopoeia commission, Ghaziabad, 2007

259. Santanu M, Mahendra DK, Vipin S. Studies on physical chemical

compatibility between synthetic and herbal drugs with various pharmaceutical

excipients. Der Pharmacia Lettre, 2011, 3(5), 173-178.

260. Pan Y, Zheng JM, Zhao HY, Li YJ, Xu H, Wei G. Relationship between

drug effects and particle size of insulin-loaded bioadhesive microspheres.

Acta Pharmacologica Sinica, 2002, 23(11),1051-1056.

261. Hui L, Changyou G. Preparation and properties of ionically cross-linked

chitosan nanoparticles. Polymers for Advanced Technologies, 2009, 20, 613-

619.

262. Jigar L, Mohan R, Manisha L, Ambikanandan M. Protein functionalized

tramadol-loaded PLGA nanoparticles preparation, optimization, stability and

pharmacodynamic studies. Drug Development and Industrial Pharmacy, 2012,

1–11.

263. Jose MB, Mariko M, Kozo T, Tsuneji N. Encapsulation of Hydrophilic and

Lipophilic Drugs in PLGA Nanoparticles by the Nanoprecipitation Method.

Drug Development and Industrial Pharmacy, 1999, 25(4), 471-476.

264. Murali MY, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin

encapsulated PLGA nanoparticles for improved therapeutic effects in

metastatic cancer cells. Journal of Colloid and Interface Science, 2010, 351,

19-29.

Bibliography


265. El-Sherbiny IM, Abdel-Mogib M, Dawidar AM. Biodegradable pH-

responsive alginate-poly (lactic-coglycolic acid) nano/micro hydrogel

matrices for oral delivery of silymarin. Carbohydrate Polymers, 2011, 83,

1345-1354.

266. Liu Z, Li J, Zeng Z, Liu M, Wang M. The antidiabetic effects of cysteinyl

metformin, a newly synthesized agent, in alloxan- and streptozocin-induced

diabetic rats. Chemico-Biological Interactions, 2008, 173, 68-75.

267. Kameswararao B, Kesavulu MM, Apparao C. Evaluation of antidiabetic

effect of Momordica cymbalaria fruit in alloxan-diabetic rats. Fitoterapia,

2003, 74, 7-13.

268. Khanna VG, Kannabiran K. Anticancer-cytotoxicity activity of saponins

isolated from the leaves of G. sylvestre and E. prostrata on HeLa cells.

International journal on Green Pharmacy, 2009, 227-229.

269. Laura G, Esther S, Maria JO, Cristina V, Cinta B, Miquel M, Mayte B, Anna

A, Santiago GV, Gerard P. Identification of Novel Human Dipeptidyl

Peptidase-IV Inhibitors of Natural Origin (PartII): In Silico Prediction in

Antidiabetic Extracts. PLoSONE. 2012, (9), doi:10.1371/journal.pone.

0044972.

270. Shrikanth HH, Manojit P. Medicinal chemistry approaches to the inhibition

of dipeptidylpeptidase-4 for the treatment of type 2 diabetes. Bioorganic &

Medicinal Chemistry, 2009, 17, 1783-1802.

271. Sutton JM, Clark DE, Dunsdon SJ, Fenton G, Fillmore A, Higgs C, Hurley

CA, Krintel SL, MacKenzie RE, Duttaroy A, Maniara W, Sedrani R, Namoto

K, Ostermann N, Gerhartz B, Trappe J, Hassiepen U, Baeschlin DK, Harris

NV, Gangl E, Sirockin F. Novel heterocyclic DPP-4 inhibitors for the

treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters,

2012, 22, 1464-1468.

272. Kaelin DE, Leiting B, Petrov A, Smenton AL, Lyons KA, Scapin G,

Weber AE, Eiermann GJ, Patel RA, Wu JK, Duffy JL, Huaibing H, Patel SB,

Thornberry NA. 4-Arylcyclohexylalanine analogs as potent, selective, and

orally active inhibitors of dipeptidyl peptidase IV. Bioorganic & Medicinal

Chemistry Letters, 2007, 17, 5806-5811.

273. Cheon HG, Sun-Mee K, Sung-Don Y, Jae DH, Joong-Kwon C. Discovery of

a novel protein tyrosine phosphatase-1B inhibitor, KR61639:potential

Bibliography


development as an antihyperglycemic agent. European Journal of

Pharmacology, 2004, 485, 333-339.

274. Ramírez-Espinosa JJ, Rios MY, Lopez-Martínez S, Lopez-Vallejo F,

Medina-Franco JL, Paoli P, Camici G, Navarrete-Vázquez G, Ortiz-Andrade

R, Estrada-Soto. Antidiabetic activity of some pentacyclic acid triterpenoids,

role of PTPe1B: In vitro, in silico, and in vivo approaches. European Journal

of Medicinal Chemistry, 2011, 46, 2243-2251.

275. Alice YYC, Fantus IG. Oral antihyperglycemic therapy for type 2 Diabetes

Mellitus. Canadian medical Association Journal, 2005, 172, 2, 213-226.

276. Kochi RB, Desaiah D, Cutkomp LK. Inhibition of ATPases by Gymnemic

acids. Chemico-Biological Interactions., 1973, 7, 121-125.

277. Ribalet B, Mirell CJ, Johnson DG, Levin SR. Sulfonylurea Binding to a

Low-affinity Site inhibits the Na/K-ATPase and the KATP Channel in Insulin-

secreting Cells. Journal of General Physiology, 1996, 107, 231-241.

278. Shimizu K, Iino A, Nakajima J, Tanaka K, Nakajyo S, Urakawa N, Atsuchi

M, Wada T, Yamashita C. Suppression of glucose absorption by some

fractions extracted from Gymnema sylvestre leaves. Journal of Veterinary

Medical Science, 1997, 59(4), 245-251.

279. Ogawa H, Shinoda T, Cornelius F, Toyoshima C. Crystal structure of the

sodium-potassium pump (Na+K+-ATPase) with bound potassium and

ouabain. Proceedings of National Acadamy of Sciences USA, 2009, 106,

13742-13747.

280. Urzhumtsev A, Tête-Favier F, Mitschler A, Barbanton J, Barth P,

Urzhumtseva L, Biellmann JF, Podjarny AD, Moras D. A „specificity‟

pocket inferred from the crystal structures of the complexes of aldose

reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.

Structure, 1997, 5, 601-612.

281. Han-Cheng Z, Hong Y, Conway BR, Derian CK, Addo MF, Gee-Hong K,

Hecker LR, Croll DR, Jian L, Westover L, Jun ZX, Look R, Demarest KT,

Andrade-Gordon P, Damiano BP, Maryanoff BE. 3-(7-Azaindolyl)-4-

arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.

Bioorganic & Medicinal Chemistry Letters, 2004, 14, 3245-3250.

282. Qing Y, Guiqing X, Dan L, Zhe C, Jia L, Yongzhou H. Synthesis and

biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen

Bibliography


synthase kinase-3b (GSK-3b) inhibitors. Bioorganic & Medicinal Chemistry,

2009, 17, 4302-4312.

283. Lagishetty C, Rajareddy K, Arumugam K, Bala TS, Srirangam R, Ramesh

M, Nuggehally RS. A rapid and highly sensitive method for the determination

of glimepiride in human plasma by liquid chromatography–electrospray

ionization tandem mass spectrometry: application to a pre-clinical

pharmacokinetic study. Biomedical Chromatography, 2008, 22, 58–63.

284. Yomiko N, Yukari T, Yasuhide T, Tadashi S. Fecal steroid excretion is

increased in rats by oral administration of Gymnemic acids contained in

Gymnema sylvestre leaves. Journal of Nutrition, 1999, 129, 1214-222.




Journal of Applied Science and Engineering, 2011, 9, 25-31.



improved method. Phytochemical Analysis, 2006, 17, 192-196.

287. Ching J, Lin HS, Tan CH, Koh HL. Quantification of α- and β-amyrin in rat

plasma by gas chromatography-mass spectrometry: application to preclinical

pharmacokinetic study. Journal of Mass Spectrometry, 2011, 46(5), 457-64.

288. Schrader E, Schwankl W, Sieder C, Christoffel V. Comparison of the

bioavailability of beta-aescin after single oral administration of two different

drug formulations containing an extract of horse-chestnut seeds. Pharmazie,

1995, 50(9), 623-7.

289. Vijayanand R, Aralelimath, Bhise SB. Anti-diabetic effects of Gymnema

sylvester extract On streptozotocin induced diabetic rats and possible β-cell

protective and regenerative evaluations. Digest Journal of Nanomaterials and

Biostructures, 2012, 7(1), 135–142.

290. Kamble B, Gupta A, Patil D, Khatal L, Janrao S, Ismail M, Duraiswamy B.

Determination of gymnemagenin in rat plasma using high performance liquid

chromatography-tandem mass spectrometry: Application to pharmacokinetics

after oral administration of Gymnema sylvestre extract. Biomedical

Chromatography, 2012, DOI 10.1002/bmc.2845.


Bibliography


291. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and

potential health effects. Advances in Food and Nutrition Research, 2009, 55,

1-99.

292. Shakyaa S, Zhua H, Dinga L, Dua XL, Qia XM, Yang XL, Yang ZL.

Determination of asperosaponin VI in dog plasma by high-performance liquid

chromatography–tandem mass spectrometry and its application to a pilot

pharmacokinetic study. Biomedical Chromatography, 2012, 26, 109-114.

293. Hana WJ, Xiaa YF, Daib Y. Development and validation of high-

performance liquid chromatography/ electrospray ionization mass

spectrometry for assay of madecassoside in rat plasma and its application to

pharmacokinetic study. Biomedical Chromatography, 2012, 26, 26–32.

294. Cai F, Sun L, Gao S, Yanga Y, Yanga Q, Chena W. A rapid and sensitive

liquid chromatography–tandem mass spectrometric method for the

determination of timosaponin BII in blood plasma and a study of the

pharmacokinetics of saponin in the rat. Journal of Pharmaceutical and

Biomedical Analysis, 2008, 48, 1411-1416.

295. Alejandro DB, Martha SB. Genotoxicity of Streptozotocin. Mutation

Research, 2002, 512, 121-134.

296. Fernandes NP, Lagishetty CV, Panda VS, Naik SR. An experimental

evaluation of the antidiabetic and antilipidemic properties of a standardized

Momordica charantia fruit extract. BMC Complementary Alternative

Medicine, 2007, 7, 29.

297. Liu Z, Li J, Zeng Z, Liu M, Wang M. The antidiabetic effects of cysteinyl

metformin, a newly synthesized agent, in alloxan- and streptozocin-induced

diabetic rats. Chemico-Biological Interactions, 2008, 173, 68-75.

298. Kirpichnikov D, Mc Farlane SI, Sowers JR. Metformin: an update. Annals of

Internal Medicine, 2002, 137, 25-33.

299. Shanmugasundaram ER, Gopinath KL, Shanmugasundaram KR, Rojendran

VM. Possible regeneration of the islets of Langerhans in streptozotocin-

diabetic rats given Gymnema sylvestre leaf extracts. Journal of

Ethnopharmacology, 1990,30, 265-279.



Bibliography




301. Shanmugasundaram KR, Panneerselvam C, Samudram P,

Shanmugasundaram ER. Enzyme changes and glucose utilisation in diabetic

rabbits: the effect of Gymnema sylvestre, R.Br. Journal of


302. Bishayee A, Chatterjee M, "Hypolipidaemic and antiatherosclerotic effect of

oral Gymnema sylvestre R.Br. leaf extract in albino rats fed on a high fat diet".

Phytotherapy Research, 1994, 8(2), 118-120.

303. Reynolds RM. Corticosteroid-mediated programming and the pathogenesis

of obesity and diabetes. Journal of Steroid Biochemistry & Molecular Biology,

2010, 122, 3-9.

304. Ardilouze JL, Pierre M, Nicole GPCR, Carpentier AC, Langlois MF,

Baillargeon JP, Adrenocortical dysregulation as a major player in insulin

resistance and onset of obesity. American Journal of Physiology,

Endocrinology and Metabolism, 293:E1465-E1478, 2007, doi:

10.1152/ajpendo.00516.2007

305. Panneerselvam K, Kodukkur VP. Antihyperglycemic effect of 18ß-

glycyrrhetinic acid, aglycone of glycyrrhizin, on streptozotocin-diabetic rats.

European Journal of Pharmacology, 2009, 606, 269-273.

306. Ko BS, Jang JS, Hong SM, Sung SR, Lee JE, Lee MY, Jeon WK, Park S.

Changes in components, Glycyrrhizin and Glycyrrhitinic acid, in raw

Glycrrhiza uralensis fish, modify insulin sensitising and insulinotropic action.

Bioscience, Biotechnology and Biochemistry, 2007, 71(6), 1452-1461.

307. http://datasheets.scbt.com/sc-205573.pdf accessed on 15-11-2012

308. http://www.mdidea.com/products/herbextract/ursolicacid/data.html accessed

on 15-11-2012

309. B. Kauppi, C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K.

Calles, O. Engstrom, J. Harlan, S. Muchmore, A. K. Ramqvist, S. Thorell, L.

Ohman, J. Greer, J. A. Gustafsson, J. C. Duke, M. Carlquist. The three

dimensional structures of antagonistic and agonistic forms of the

Glucocorticoid receptor ligand-binding domain. The Journal of Biological

Chemistry, 2003, 278(25), 22748-22754.

http://datasheets.scbt.com/sc-205573.pdf%20accessed%20on%2015-11-2012

http://www.mdidea.com/products/herbextract/ursolicacid/data.html%20accessed%20on%2015-11-2012

http://www.mdidea.com/products/herbextract/ursolicacid/data.html%20accessed%20on%2015-11-2012

Bibliography


310. Link JT, Bryan S, Jyoti P, Marlena G, Annika GN, Jiahong W, Steven F,

Denise W, Brad Z, Phong N, Bach H, Schmidt JM, Sue S, Zhenping T,

Thomas JR, Gary R, Jia D, Benjamin L, Geldern TWV and Jacobson PB.

Antidiabetic Activity of Passive Nonsteroidal Glucocorticoid Receptor

Modulators. Journal of Medicinal Chemistry, 2005, 48, 5295-5304.

311. Chang HY, Wallis M, and Tiralongo E. Use of complementary and

alternative medicine among people living with diabetes: literature review.

Journal of Advanced Nursing, 2007, 58(4), 307–319.

312. Mehrotra R, Bajaj S, Kumar D. Use of complementary and alternative

medicine by patients with diabetes mellitus. National Medical Journal of

India, 2004, 17(5), 243-5.

313. Zhou S, Zhou W, Li C, Chen X, Yu X, Xue C, Herington A. Identification

of drugs that interacts with herbs in drug development. Drug Discovery Today,

2007, 12, 664-673.

314. Gardiner P, Phillips R, Shaughnessy AF. Herbal and dietary supplement-

drug interactions in patients with chronic illnesses. American Family

Physician, 2008, 77, 73-78.

315. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ.

Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and

pharmacodynamics of gliclazide. British Journal of Pharmacology, 2008,

153, 1579-1586.

316. Nishimura N, Naora K, Hirano H, Iwamoto K. Effects of Sho-saiko-to on

the pharmacokinetics and pharmacodynamics of tolbutamide in rats. Journal

of Pharmacy and Pharmacology, 1998, 50, 231-236.





318. Shanmugasundaram KR, Panneerselvam C, Samudram P,

Shanmugasundaram ER. Enzyme changes and glucose utilisation in diabetic

rabbits: the effect of Gymnema sylvestre, R.Br. Journal of


http://www.ncbi.nlm.nih.gov/pubmed?term=Mehrotra%20R%5BAuthor%5D&cauthor=true&cauthor_uid=15638303

http://www.ncbi.nlm.nih.gov/pubmed?term=Bajaj%20S%5BAuthor%5D&cauthor=true&cauthor_uid=15638303

http://www.ncbi.nlm.nih.gov/pubmed?term=Kumar%20D%5BAuthor%5D&cauthor=true&cauthor_uid=15638303



Bibliography


319. Krauss H, Jacek K, Marian G, Premyslaw S, Kinga M, Jacek P, Janusz P.

The influence of glimepiride on the oxidative state of rats with streptozotocin-

induced hyperglycemia. Medical Science Monitor, 2003, 9, 389-393.

320. Haupt A, Kausch C, Dahl D, Bachmann O, Stumvoll M, Haring Hans-U,

Matthael S. Effect of Glimepiride on insulin stimulated glycogen synthesis in

cultured human skeleton muscle cells. A comparision to glibenclamide.

Diabetes care, 2002, 25, 2129-2132.

321. Krauss H, Jacek K, Marian G, Premyslaw S, Kinga M, Jacek P, Janusz P.

The influence of glimepiride on the oxidative state of rats with streptozotocin-

induced hyperglycemia. Medical Science Monitor, 2003, 9, 389-393.

322. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-a

comparison between glimepiride and conventional sufonylureas. Diabetes

Research and Clinical Practice, 1995, S, 115-37.

323. Yamazoe Y, Murayama N, Shimada M, Yamauchi K, Kato R. Cytochrome

P450 in livers of diabetic rats: regulation by growth hormone and insulin.

Archives of Biochemistry and Biophysics, 1998, 268, 567-575.

324. Vega P, Gaule C, Mancilla J, Del Villar E. Comparison of alloxan and

streptozotocin induced diabetes in rats: differential effects on microsomal drug

metabolism. General Pharmacology, 1993, 24, 489-495.

325. Nawa A, Fujita-Hamabe W, Kishioka S, Tokuyama S. Decreased

expression of intestinal P-glycoprotein increases the analgesics effects of oral

morphine in a streptozotocin-induced diabetic mouse model. Drug Metabolism

and Pharmacokinetics., 2011, 26(6), 584-591.

.

Documents

Harvey AL. Natural products in drug discovery. 2008 …shodhganga.inflibnet.ac.in/bitstream/10603/9420/13/13_bibliography.pdfHarvey AL. Natural products in drug discovery. Drug Discovery